N-(2-aminoethyl)acetamide → N-[2-(acetylamino)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide
Reaction equation
[F:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][C:9]2[CH:18]=[C:17]3[C:12]([C:13]([OH:29])=[C:14]([C:24](OCC)=[O:25])[C:15](=[O:23])[N:16]3[CH2:19][CH2:20][CH2:21][OH:22])=[N:11][CH:10]=2)=[CH:4][CH:3]=1.[NH2:30][CH2:31][CH2:32][NH:33][C:34](=[O:36])[CH3:35]>>[C:34]([NH:33][CH2:32][CH2:31][NH:30][C:24]([C:14]1[C:15](=[O:23])[N:16]([CH2:19][CH2:20][CH2:21][OH:22])[C:17]2[C:12]([C:13]=1[OH:29])=[N:11][CH:10]=[C:9]([CH2:8][C:5]1[CH:4]=[CH:3][C:2]([F:1])=[CH:7][CH:6]=1)[CH:18]=2)=[O:25])(=[O:36])[CH3:35]Participants
3
Procedure
In a similar manner to that described in example 196, from ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (60 mg, 0.15 mmol) and N-(2-aminoethyl)acetamide (100 mg, 0.99 mmol) was prepared N-[2-(acetylamino)ethyl]-7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(3-hydroxypropyl)-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (21 mg, 31% yield) as a tan solid after purification by reverse phase HPLC. 1H NMR (methanol-d4/CDCl3) δ 10.18 (br s, 1 H), 8.40 (s, 1 H), 7.56 (s, 1 H), 7.09-7.05 (m, 2 H), 6.94-6.88 (m, 2 H), 4.21 (m, 2 H), 4.04 (s, 2 H), 7.70 (m, 2 H), 3.46 (m, 2 H), 3.33 (m, 2 H), 1.86 (s, 3 H), 1.74 (m, 2 H); MS m/z 457 M+1).
Sources & evidence
- ORD record
- ord-2a110ff26e2744e4906d5276562bbf18
- Source dataset
- uspto-grants-2014_04
- Patent number
- US08691991B2
Reaction notes
Loading…